Doxil® is the liposomal formulation of doxorubicin, approved for the management of Kaposi’s sarcoma as well as refractory breast and ovarian cancer, while Abraxane® is an albumin-based nanoparticles (NPs) of paclitaxel and approved for the management of metastatic breast cancer. Here, ALB is linked to ovarian carcinoma.